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https://doi.org/10.1016/j.jacl.2017.12.0BACKGROUND: Higher visit-to-visit variability in risk factors such as blood pressure and low-
density lipoprotein (LDL)-cholesterol are associated with an increase in cardiovascular (CV) events.
OBJECTIVE: The purpose of this study was to determine whether variability in high-density lipopro-
tein cholesterol (HDL-C) and triglyceride levels predicted coronary and CV events in a clinical trial
population with known coronary disease.
METHODS: We assessed intraindividual variability in fasting high-density lipoprotein (HDL)-
cholesterol, triglyceride, and LDL-cholesterol measurements among 9572 patients in the Treating to
New Targets trial and correlated the results with coronary events over a median follow-up of 4.9 years.
RESULTS: In the fully adjusted Cox model, 1 standard deviation of average successive variability,
defined as the average absolute difference between successive values, was associated with an increased
risk of a coronary event for HDL-cholesterol (hazard ratio [HR] 1.16, 95% confidence interval [CI]
1.11–1.21, P , .0001), for triglycerides (HR 1.09, 95% CI 1.04–1.15, P 5 .0005), and for
LDL-cholesterol (HR 1.14, 95% CI 1.09–1.19, P , .0001). Similar results were found for the 3 other
measures of variability, standard deviation, coefficient of variability, and variability independent of the
mean. Similar results were seen for CV events, stroke, and nonfatal myocardial infarction. Higher
variability in triglyceride and LDL-cholesterol, but not HDL-cholesterol, was predictive of incident
diabetes. The correlation among the variability of the 3 lipid measurements was weak.
CONCLUSION: Visit-to-visit variability in fasting measurements of HDL-cholesterol, triglycerides,
and LDL-cholesterol are predictive of coronary events, CVevents, and for triglyceride and low-density
lipoprotein cholesterol variability, incident diabetes. The mechanisms accounting for these associations
remain to be determined.
 2017 National Lipid Association. All rights reserved.sponsored by Pfizer.
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Author's Personal CopyHigh levels of biological variables, including blood
pressure (BP), low-density lipoprotein cholesterol (LDL-C),
and body weight are associated with an increased risk of
cardiovascular (CV) events, and lowering these levels has
been shown to reduce CV risk. In addition, variability in these
measurements is predictive of CV events; for example, long-
term variability in systolic BP is associated with increased all-
cause and CV mortality, as well as CV events, including
coronary events and stroke.1,2 Long-term variability of total
cholesterol levels increased risk in the Framingham popula-
tion,3 and in patients with coronary disease LDL-C variability
has been related to an increase in CV events.4,5 In both
Framingham and in coronary patients, variations in body
weight are also associated with a higher rate of CV events.6,7
Although low high-density lipoprotein cholesterol (HDL-
C) and high triglyceride levels are known risk factors for CV
events, whether variability in HDL-C and triglyceride levels
are linked to increased CV risk has not been investigated.
The primary purpose of this study is to determine whether
HDL-C variability and triglyceride variability predict coro-
nary and CV events, and incident diabetes in patients in the
Treating to New Targets (TNT) trial, a well-characterized
population where LDL-C variability has already been related
to CV events.4 Secondary purposes include examining the
correlation among LDL-C, HDL-C and triglyceride vari-
ability and assessing the relative strength of these measures
of variability in predicting CV events.Methods
Patient population
This study is a post hoc analysis of the TNT trial, where
10,001 patients aged 35 to 75 years with clinically evident
coronary disease were randomly assigned to atorvastatin
10 mg or 80 mg/d and followed up for a median of 4.9 years.
Inclusion criteria included an LDL-C of 130–250 mg/dL and
a triglyceride level #600 mg/dL before treatment, and an
LDL-C,130 mg/dL after an 8-week run-in period while
taking atorvastatin 10 mg/d. The study design and principal
results have previously been reported.8,9 The institutional
review board at each of the 256 sites approved the trial,
and written informed consent was obtained from each
patient. The TNT trial is registered on clinicaltrials.gov
(NCT00327691).
Lipid variability measurements
Follow-up visits were scheduled at week 12 and at
months 6, 9, and 12 during the first year and then every
6 months thereafter. Blood for lipids were drawn after a
12-hour fast at the week 12 visit, at 12 months, and then
annually. Lipids were measured in a central laboratory using
standard techniques. LDL-C was measured directly when
serum triglycerides exceeded 400 mg/dL but otherwise was
calculated using the Friedewald equation. Subjects with atleast 2 postbaseline lipid measurements were included in this
analysis. Measurements of HDL-C, triglyceride, and LDL-C
levels from the 12-week visit onward were used to calculate
visit-to-visit variability because lipid levels in the 2 treat-
ment arms had stabilized by 12 weeks.
Four measurements of variability were calculated: (1)
the average successive variability (ASV), defined as the
average absolute difference between successive values of
the available HDL-C, triglyceride, or LDL-C levels; (2) the
standard deviation (SD) of successive measurements; (3)
the coefficient of variation (CV); and (4) variability inde-
pendent of the mean (VIM). VIM was calculated as 100!
SD/meanbeta, where beta is the regression coefficient, on the
basis of natural logarithm of SD on natural logarithm of
mean. This uncorrected VIM was corrected using the
formula (VIM uncorrected ! [mean of CV])/(mean of
VIM uncorrected). The results with each of these 4
measurements of variability were relatively similar, so for
the sake of simplicity, mainly ASV results are presented.
The primary outcome for this study was the occurrence of
any coronary event, defined as coronary heart disease death,
nonfatal myocardial infarction (MI), resuscitated cardiac
arrest, revascularization, or angina. The secondary outcomes
were any CV event (any coronary event or cerebrovascular
event, peripheral vascular disease, hospitalization for heart
failure), death, MI, stroke, or incident diabetes.
Statistical analysis
Baseline characteristics were compared between patients
above and below median variability for HDL-C, triglyceride,
and LDL-C variability using chi-square tests for categorical
variables and 1-way analysis of variance for continuous
variables. The relation between HDL-C, triglyceride, and
LDL-C variability (continuous variable) and the risk of
outcomes were evaluated using a Cox proportional hazards
regression model. Four models were constructed (separately
for HDL-C, triglycerides, and LDL-C): model 1, unadjusted
model; model 2, adjusting model 1 for treatment effect
(atorvastatin 80 mg vs 10 mg/d); model 3, adjusting model 2
to mean HDL-C, triglyceride, or LDL-C variability values
(continuous), and model 4, where the following additional
adjustments were added to model 3: age, gender, race,
baseline body mass index, diabetes, hypertension, chronic
kidney disease, heart failure, smoking status, LDL-C,
HDL-C, total cholesterol, and triglycerides. An additional
model was constructed including all the variables in model
4, plus the change in HDL-C, triglyceride, or LDL-C from
week 12 to the end of follow-up. The results of this model
were almost identical to model 4, and these results are thus
not presented. Patients with events in the first 3 months were
excluded from analysis.
For HDL-C, triglyceride, and LDL-C variability,
patients were divided into quintiles of ASV, SD, CV, and
VIM for the primary and secondary end points. For each of
these analyses, the same adjustments were made as for the
Cox proportional hazards regression model. All analyses
358 Journal of Clinical Lipidology, Vol 12, No 2, April 2018
Author's Personal Copywere performed with the use of SAS software, version 9.0
(SAS Institute, Cary, NC). A value of P , .05 (2 sided) was
considered statistically significant.
Results
Of the 10,001 patients included in the TNT trial, 9572
had at least 2 postbaseline lipid measurements and are
included in this analysis. Lipid levels were similar in the 2
treatment groups at baseline, but after 12 weeks of
treatment, triglycerides were lower in the 80 mg compared
to the 10 mg group (128 6 65 mg/dL vs 152 6 79 mg/dL)
as was LDL-C (73 6 21 mg/dL vs 99 6 20 mg/dL). HDL-
C levels at 12 weeks were similar (47 6 11 mg/dL).
The clinical features of patients with ASV values below
and above the median for HDL-C, triglycerides, and LDL-
C are listed in Tables 1–3, respectively. Patients with HDL-
C variability above the median were more likely to be
women and to have higher HDL-C levels after 3 months
of treatment. Patients with triglyceride variability above
the median were younger and more likely to have diabetes
compared to patients below the median. On treatment, their
HDL-C levels were lower, their LDL-C levels higher, and
their triglyceride levels much higher compared to patients
below the median. Patients with higher LDL-C variability
were more likely to be women and to have higher on-
treatment LDL-C and triglyceride levels.Table 1 Clinical features of patients with ASV of HDL-C above and
Clinical features ASV # 4 (n 5 5166)
Age (years) 60.7 6 8.8
Female 736 (14.3%)
Caucasian 4876 (94.4%)
Diabetes 745 (14.4%)
Hypertension 2742 (53.1%)
Current smoker 670 (13.0%)
Previous CABG 2428 (47.0%)
Previous PCI 2792 (54.1%)
Heart failure 367 (7.1%)
BMI 28.8 6 4.5
Systolic BP (mm Hg) 130.4 6 16.8
Diastolic BP (mm Hg) 78.1 6 9.3
On-treatment (3 mo)
LDL-C (mg/dL) 85.0 6 24.0
HDL-C (mg/dL) 43.9 6 8.8
Triglycerides (mg/dL) 143 6 71
CKD 1589 (30.8%)
MDRD 65.4 6 11.1
ASV HDL-C 2.71 6 0.86
ASV LDL-C 12.2 6 8.6
ASV triglycerides 37.3 6 32.0
ASV, average successive variability; BMI, body mass index; BP, blood press
HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein chol
filtration rate; PCI, percutaneous coronary intervention.HDL-C variability and end point events
For each 1 SD increase in ASV of HDL-C, the risk of
any coronary event increased in the unadjusted Cox model
(hazard ratio [HR] 1.06, 95% confidence interval [CI]
1.02–1.10, P 5 .0053), as shown in Figure 1. Adjusting for
treatment group, mean HDL-C, and clinical covariates
(model 4) increased the risk (HR 1.16, 95% CI
1.11–1.21, P , .0001). Similar results were seen for the
other measures of variability: SD, CV, and VIM, as shown
in Figure 1.
Higher quintiles of ASV for HDL-C were associated with
an increased risk for any coronary event, as shown in
Figure 2. After adjusting for treatment group, mean HDL-C,
and clinical covariates (model 4), the risk was 50% higher in
quintile 5 compared to quintile 1 (HR 1.50, 95% CI
1.30–1.74, P , .0001). Quintile 5 included patients with
an HDL-C ASV of 6.1 and higher. Similar results were
seen for the other measures of variability (not shown).
Quintiles of ASV for HDL-C are also shown in Figure 2
for the broader secondary end point, any CV event, and for
stroke, nonfatal MI, all-cause mortality, and new-onset
diabetes. For each of these end points except new-onset
diabetes, the HR was higher in quintile 5 compared to
quintile 1, ranging from 1.56 to 1.81, and in each case,
the trend across quintiles was highly statistically
significant.below the median
ASV . 4 (n 5 4406) P value
61.4 6 8.9 .0004
1066 (24.2%) ,.0001
4144 (94.1%) .51
672 (15.3%) .26
2421 (55.0%) .077
589 (13.4%) .56
2018 (45.8%) .25
2397 (54.4%) .74
355 (8.1%) .081
28.2 6 4.5 ,.0001
131.0 6 16.7 .064
77.8 6 9.6 .061
86.1 6 24.8 .024
51.3 6 12.4 ,.0001
136 6 74 ,.0001
1486 (33.7%) .002
65.2 6 11.6 .22
6.70 6 3.1 ,.0001
14.7 6 10.2 ,.0001
42.2 6 44.2 ,.0001
ure; CABG, coronary artery bypass grafting; CKD, chronic kidney disease;
esterol; MDRD, Modification of Diet in Renal Disease estimated glomerular
Table 2 Clinical features of patients with ASV of triglycerides above and below the median
Clinical features ASV # 30 (n 5 4802) ASV . 30 (n 5 4770) P value
Age (years) 62.1 6 8.6 59.9 6 8.9 ,.0001
Female 896 (18.7%) 906 (19.0%) .68
Caucasian 4494 (93.6%) 4526 (94.9%) .0065
Diabetes 565 (11.8%) 852 (17.9%) ,.0001
Hypertension 2448 (51.0%) 2715 (56.9%) ,.0001
Current smoker 542 (11.3%) 717 (15.0%) ,.0001
Previous CABG 2180 (45.4%) 2266 (47.5%) .040
Previous PCI 2540 (52.9%) 2649 (55.5%) .0097
Heart failure 309 (6.4%) 413 (8.7%) ,.0001
BMI 27.9 6 4.4 29.1 6 4.6 ,.0001
Systolic BP (mm Hg) 130.6 6 17.1 130.8 6 16.3 .67
Diastolic BP (mm Hg) 77.5 6 9.6 78.4 6 9.3 ,.0001
On-treatment (3 mo)
LDL-C (mg/dL) 82.4 6 23.4 88.5 6 24.8 ,.0001
HDL-C (mg/dL) 49.3 6 11.6 45.3 6 10.5 ,.0001
Triglycerides (mg/dL) 109 6 42 171 6 83 ,.0001
CKD 1517 (31.6%) 1558 (32.7%) .26
MDRD 65.5 6 11.2 65.2 6 11.5 .22
ASV HDL-C 4.47 6 2.9 4.62 6 3.0 .014
ASV LDL-C 11.6 6 7.7 15.1 6 10.6 ,.0001
ASV triglycerides 18.6 6 6.8 60.6 6 44.6 ,.0001
ASV, average successive variability; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CKD, chronic kidney disease;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MDRD, Modification of Diet in Renal Disease estimated glomerular
filtration rate; PCI, percutaneous coronary intervention.
Table 3 Clinical features of patients with ASV of LDL-C above and below the median
Clinical features
ASV # 11.12
(n 5 4786)
ASV . 11.2
(n 5 4786) P value
Age (y) 61.7 6 8.6 60.4 6 9.0 ,.0001
Female 792 (16.6%) 1010 (21.1%) ,.0001
Caucasian 4552 (95.1%) 4468 (93.4%) .0003
Diabetes 631 (13.2%) 786 (16.4%) ,.0001
Hypertension 2514 (52.5%) 2649 (55.4%) .0060
Current smoker 576 (12.0%) 683 (14.3%) .0013
Previous CABG 2219 (46.4%) 2227 (46.5%) .89
Previous PCI 2583 (54.0%) 2606 (54.5%) .65
Heart failure 327 (6.8%) 395 (8.3%) .0095
BMI 28.4 6 4.4 28.7 6 4.6 .0015
Systolic BP (mm Hg) 130.5 6 16.7 130.9 6 16.8 .29
Diastolic BP (mm Hg) 77.8 6 9.4 78.2 6 9.5 .037
On-treatment (3 mo)
LDL-C (mg/dL) 80.2 6 21.8 90.7 6 25.6 ,.0001
HDL-C (mg/dL) 47.3 6 11.1 47.3 6 11.3 .98
Triglycerides (mg/
dL)
129 6 61 151 6 82 ,.0001
CKD 1530 (32.0%) 1545 (32.3%) .76
MDRD 65.2 6 11.0 65.4 6 11.6 .48
ASV HDL-C 4.15 6 2.6 4.95 6 3.2 ,.0001
ASV LDL-C 7.3 6 2.3 19.3 6 10.0 ,.0001
ASV triglycerides 32.1 6 25.0 47.0 6 46.7 ,.0001
ASV, average successive variability; BMI, body mass index; BP, blood pressure; CABG, coronary artery bypass grafting; CKD, chronic kidney disease;
HDL-C, high-density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; MDRD, Modification of Diet in Renal Disease estimated glomerular
filtration rate; PCI, percutaneous coronary intervention.
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Figure 1 Risk of a coronary event in unadjusted and adjusted Cox regression models for 1 standard deviation of 4 measures of HDL-C
variability: ASV, SD, CV, and VIM. *Baseline factors included age, sex, race, BMI, diabetes mellitus, hypertension, smoking status, LDL-
C, HDL-C, total cholesterol, triglycerides, chronic kidney disease, and heart failure. ASV, average successive variability; CV, cardiovascular;
HDL-C, high-density lipoprotein cholesterol; SD, standard deviation; VIM, variability independent of the mean.
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Author's Personal CopyTriglyceride variability and end point events
For each 1 SD increase in ASV of triglycerides, the risk
of any coronary event increased in the unadjusted Cox
model (HR 1.11, 95% CI 1.08–1.14, P , .0001), as shown
in Figure 3. Adjusting for treatment group, mean triglycer-
ide level, and clinical covariates (model 4) slightly
decreased the risk (HR 1.09, 95% CI 1.04–1.15,
P 5 .0005). Similar results were seen for the other mea-
sures of variability: SD, CV, and VIM, as shown in
Figure 3.Quintile 5 of ASV for triglyceride levels was associated
with an increased risk for any coronary event compared to
quintile 1 in model 4 (HR 1.35, 95% CI 1.14–1.60,
P 5 .0006), as shown in Figure 4. Quintile 5 included pa-
tients with a triglyceride ASV of 53.7 and higher. Similar
results were seen for the other measures of variability
(not shown). For triglyceride variability, the increase in
risk appeared to reside mainly in quintile 5, with risk in
quintiles 1–4 being lower and approximately equal.
Quintiles of ASV for triglycerides are also shown in
Figure 4 for the other study end points. For any CV event,
Figure 2 Risk of various events during follow-up in ASV quintiles of HDL-C variability. Results were similar for the other 3 measures of
variability. Quintile 5 was associated with an increased risk for each end point except incident diabetes. *Adjusted for treatment 1 mean
HDL-C 1 baseline factors (age, sex, race, BMI, diabetes mellitus, hypertension, smoking status, LDL-C, HDL-C, total cholesterol, triglyc-
erides, chronic kidney disease, and heart failure). ASV, average successive variability; CV, cardiovascular; HDL-C, high-density lipoprotein
cholesterol.
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Figure 3 Risk of a coronary event in unadjusted and adjusted Cox regression models for 1 standard deviation of 4 measures of triglyc-
eride variability: ASV, SD, CV, and VIM. *Baseline factors included age, sex, race, BMI, diabetes mellitus, hypertension, smoking status,
LDL-C, HDL-C, total cholesterol, triglycerides, chronic kidney disease, and heart failure. ASV, average successive variability; CV, cardio-
vascular; SD, standard deviation; VIM, variability independent of the mean.
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Author's Personal Copyand for stroke, non-fatal MI, and incident diabetes, the HR
was higher in quintile 5 compared to quintile 1, ranging
from 1.31 to 1.98, and in each case, the trend across quin-
tiles was statistically significant. For all-cause mortality, a
trend in the opposite direction was observed, with a lower
HR in quintile 5 compared to quintile 1 (HR 0.89, 95%
CI 0.64–1.25, P 5 .51). This finding may be a result of
the shorter follow-up and thus fewer lipid measurements
among patients who died.LDL-C variability and end point events
The relationship between LDL-C variability and events
has already been reported4 and is summarized here only for
comparison. For each 1 SD increase in ASVof LDL-C, the
risk of any coronary event increased in the unadjusted Cox
model (HR 1.14, 95% CI 1.10–1.18, P , .0001) and in
model 4, adjusted for treatment group, mean HDL-C, and
clinical covariates (HR 1.14, 95% CI 1.09–1.19,
Figure 4 Risk of various events during follow-up in ASV quintiles of triglyceride variability. Results were similar for the other 3 mea-
sures of variability. Quintile 5 was associated with an increased risk for each end point except all-cause mortality. *Adjusted for
treatment 1 mean TG 1 baseline factors (age, sex, race, BMI, diabetes mellitus, hypertension, smoking status, LDL-C, HDL-C, total
cholesterol, triglycerides, chronic kidney disease, and heart failure). ASV, average successive variability.
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Author's Personal CopyP , .0001). Similar results were seen for the other mea-
sures of variability: SD, CV, and VIM (data not shown).
Higher quintiles of ASV for LDL-C were associated
with an increased risk for any coronary event. After
adjusting for treatment group, mean LDL-C, and clinical
covariates (model 4), the risk was 24% higher in quintile 5
compared to quintile 1 (HR 1.25, 95% CI 1.07–1.44,
P 5 .0037). Similar results were seen for the other
measures of variability (not shown). For the other study
end points, the risk in quintile 5 compared to quintile 1
was 27% to 31% higher, although the increase was not sta-
tistically significant for stroke, nonfatal MI, or all-cause
mortality. For incident diabetes, the HR for quintile 5
compared to quintile 1 for ASV of LDL-C was 1.30 (95%
CI 0.99–1.71, P 5 .060).
Relationships between triglyceride, HDL-C, and
LDL-C variability
The Pearson correlation coefficients among triglyceride,
HDL-C, and LDL-C variability were all weak but highly
statistically significant due to the large numbers. The
correlation between triglycerides and HDL-C variability
was 0.046, between triglycerides and LDL-C variability
was 0.26, and between HDL-C and LDL-C variability was
0.16 (P , .0001 for all). Similar results were seen for SD.
In a model adjusted for treatment group, mean HDL-C,
triglyceride, and LDL-C levels, and clinical covariates
(model 4), and containing measures of HDL-C, triglyceride,
and LDL-C variability, HDL-C and LDL-C variability
remained robust predictors of time to first coronary event:
the HR for 1 SD increase in ASV for HDL-C was 1.13 (95%
CI 1.07–1.18, P , .0001) and for LDL-C was 1.10 (95% CI
1.05–1.16, P , .0001). Triglyceride variability was a weaker
predictor: the HR for 1 SD increase in ASV for triglycerides
was 1.05 (95% CI 1.00–1.11, P 5 .0495).Discussion
The results of this study indicate that measures of visit-
to-visit variability of triglycerides, HDL-C, and LDL-C are
each predictive of coronary and CV events. The 4 measures
of variability used in this study, ASV, SD, CV, and VIM, all
yielded similar results. The ability of these measurements
to predict events persisted after adjustment for treatment
group (atorvastatin 10 mg or 80 mg/d), treatment group
plus mean triglyceride, HDL-C or LDL-C level, and
treatment group, mean lipid level, and a long list of
clinical covariates: age, sex, race, BMI, diabetes, hyper-
tension, current smoking, chronic kidney disease, heart
failure, LDL-C, HDL-C, total cholesterol, and triglyceride
levels.
After these adjustments, the incremental risk for any
coronary event for quintile 5 vs quintile 1 of ASV was 35%
for triglycerides, 50% for HDL-C, and 24% for LDL-C.
The incremental risk for triglycerides was 66% for strokeand 66% for nonfatal MI, and for HDL-C, it was 75% for
stroke and 62% for nonfatal MI. This robust predictive
power does not mean that variability in lipid measurements
would be useful clinically for risk prediction because most
risk predictors used in clinical practice are readily avail-
able, and the mechanism whereby the factor increases risk
is understood. Such is not the case for lipid variability.
Mechanism of action
How variability in HDL-C, triglyceride, and LDL-C
measurements relates to an increase in coronary events is
unknown. All patients in this study were taking atorvastatin,
and incomplete adherence to treatment would result in higher
variability of LDL-C and triglyceride measurements. How-
ever, patients in a clinical trial tend to be more compliant
with treatment compared to the usual clinical setting, and in
our previous study of LDL-C variability,4 the variability
measures were predictive of events even after controlling
for medication adherence. In any case, statins have compar-
atively little long-term effect on HDL-C, and thus, medica-
tion noncompliance is a poor explanation for HDL-C
variability. Subjects who do discontinue statins have been
shown to be at higher risk for subsequent MI and CV death.10
Interestingly, variability of one lipid measurement did
not correlate well with the variability of the others. This
suggests that the mechanisms causing higher variability of
HDL-C measurements, for example, may differ from the
mechanisms causing higher variability in LDL-C or
triglyceride measurements.
Higher levels of HDL-C, triglycerides, and LDL-C were
associated with higher variability of each parameter. Other-
wise, the clinical features of patients with HDL-C or LDL-C
variability above and below the median (Tables 1–3) were
generally unremarkable. However, patients with triglyceride
variability above the median were younger, more likely had
diabetes and a higher BMI, and had higher LDL-C and lower
HDL-C levels, as well as much higher triglyceride levels,
compared to those below the median. The metabolic syn-
drome is thus likely associated with high triglyceride
variability.
Another potential mechanism of this increased risk is that
lipid variability is an epiphenomenon of other conditions that
increase CV risk. Perhaps patients with systemic conditions
causing general frailty might have higher variability of
multiple biological parameters and increased risk caused by
several pathologic mechanisms. If higher variability were
related to frailty, patients with increased variability might be
expected to be older, but they were not in this study.
Triglyceride levels vary widely during the day, mainly in
relation to meals, and nonfasting triglyceride levels predict
CVevents at least as well as fasting levels do.11,12 Postpran-
dial hypertriglyceridemia induces transient endothelial
dysfunction, a marker of early atherosclerosis.13,14 This
short-term variability in fasting triglycerides is different
than the visit-to-visit variability described in this study.
Given the high short-term variability in triglycerides, it is
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importance.
Incident diabetes
High triglyceride levels, but not high LDL-C or low
HDL-C levels, have been shown to be an independent risk
factor for incident diabetes in the TNT population.15 In this
study, triglyceride variability, but not HDL-C variability,
was predictive of incident diabetes in the model adjusted
for treatment group, mean lipid level, and clinical features.
Many clinical and laboratory markers that predict incident
diabetes have been identified, and high triglyceride
variability might be associated with one or more of them.
As noted previously, high triglyceride variability was asso-
ciated with features of the metabolic syndrome in this
study, and the metabolic syndrome is a strong predictor
of incident diabetes.
Previous studies
The amount of variability in clinical lipid measurements
has been well documented.16–18 A fixed component of this
variability is due to laboratory measurement variability, but
most is due to intrapatient variability.16 In contrast to BP vari-
ability, where many studies have reported an association be-
tween high variability and CVevents, few reports have linked
variability in lipid measurements to CVevents.19,20 In a study
of 130 survivors of ST segment-elevation MI, LDL-C, and
HDL-C predicted CV events over a 5-year follow-up.19
In a study of 4428 participants of Prospective Study of
Pravastatin in theElderly at Risk, higherLDL-Cvariabilitywas
recently found to be associated with lower cognitive function
and lower cerebral blood flow in both the placebo and
pravastatin treatment arms.20 HDL-C and triglyceride vari-
ability were not reported in this study, and the authors specu-
lated on potential mechanisms that could explain their findings.
Limitations of the study
The results of this study were derived from a clinical
trial where conditions differ from clinical practice. Lipids
were measured after a 12-hour fast and analyzed in a
central laboratory. The study patients all had documented
coronary disease and were taking atorvastatin. We used 4
measures of variability and all 4 yielded roughly similar
results. However, it is not known whether or not our
findings could be duplicated under other conditions, such as
clinical practice. The variability measurements do not take
into account the direction of the change; however, adjusting
for change in lipid values from week 12 to the end of the
study did not alter our findings.
As a retrospective analysis of a clinical trial, our study
does not provide an explanation for its findings. How
variability in HDL-C, triglyceride, and LDL-C measurements
relate to coronary events or incident diabetes appears to be a
fruitful topic for further investigation.Conclusions
Visit-to-visit variability in fasting measurements of
HDL-cholesterol, triglycerides, and LDL-cholesterol are
predictive of coronary events, CVevents, and for triglyceride
and LDL-C variability, incident diabetes. The mechanisms
accounting for these associations remain to be determined.Acknowledgments
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